LARP6 and Bartsocas-Papas syndrome 1: It was demonstrated in an in vitro experiment by Zuo et al. [47] that bumetanide could inhibit collagen biosynthesis in fibroblasts by targeting the interaction of CRTH2 and LARP6, resulting in the treatment of organ fibrosis, suggesting that bumetanide may alleviate symptoms of IC/BPS patients by inhibiting bladder fibrosis.